Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Mirum Pharmaceuticals Priced 3.478M Share Public Offering of Common Stock @$23/Share
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Mirum Pharmaceuticals Highlights Data From Livmarli (maralixibat) On Patients With Alagille Syndrome At European Society For Paediatric Gastroenterology, Hepatology And Nutrition Annual Meeting
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual
SVB Leerink Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $52
SVB Leerink analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $50 to $52.
Expert Ratings for Mirum Pharmaceuticals
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings:
Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $75
Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and raises the price target from $74 to $75.
83 Biggest Movers From Yesterday
Gainers
Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.
